Human CDK1/CyclinA1 Active

Description

Human CDK1/CyclinA1 Active
Catalog number: B2013946
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 10 μg
Molecular Weight or Concentration: 58 kDa (CDK1)
81 kDa (CyclinA1)
Supplied as: Solution
Applications: molecular tool for various biochemical applications
Storage: −20°C
Keywords: CCNA1, CDC2
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Haneke K, Schott J, Lindner D, Hollensen AK, Damgaard CK, Mongis C, Knop M, Palm W, Ruggieri A, Stoecklin G. CDK1 couples proliferation with protein synthesis J Cell Biol. 2020 Mar 2;219(3):e201906147.
2: Michowski W, Chick JM, Chu C, Kolodziejczyk A, Wang Y, Suski JM, Abraham B, Anders L, Day D, Dunkl LM, Li Cheong Man M, Zhang T, Laphanuwat P, Bacon NA, Liu L, Fassl A, Sharma S, Otto T, Jecrois E, Han R, Sweeney KE, Marro S, Wernig M, Geng Y, Moses A, Li C, Gygi SP, Young RA, Sicinski P. Cdk1 Controls Global Epigenetic Landscape in Embryonic Stem Cells Mol Cell. 2020 May 7;78(3):459-476.e13.
3: Xie B, Wang S, Jiang N, Li JJ. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance Cancer Lett. 2019 Feb 28;443:56-66.
4: Galarreta A, Valledor P, Ubieto-Capella P, Lafarga V, Zarzuela E, Muoz J, Malumbres M, Lecona E, Fernandez-Capetillo O. USP7 limits CDK1 activity throughout the cell cycle EMBO J. 2021 Jun 1;40(11):e99692.
5: Ren L, Yang Y, Li W, Zheng X, Liu J, Li S, Yang H, Zhang Y, Ge B, Zhang S, Fu W, Dong D, Du G, Wang J. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis J Transl Med. 2022 Oct 2;20(1):444.
6: Sunada S, Saito H, Zhang D, Xu Z, Miki Y. CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity Biochem Biophys Res Commun. 2021 Apr 23;550:56-61.
7: Huang Z, Shen G, Gao J. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2 Clin Transl Oncol. 2021 Sep;23(9):1743-1751.
8: Zou Y, Ruan S, Jin L, Chen Z, Han H, Zhang Y, Jian Z, Lin Y, Shi N, Jin H. CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma Med Sci Monit. 2020 Aug 31;26:e925289.
9: Lu X, Pang Y, Cao H, Liu X, Tu L, Shen Y, Jia X, Lee JC, Wang Y. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors Cancer Res. 2021 May 1;81(9):2481-2494.
10: Wu CX, Wang XQ, Chok SH, Man K, Tsang SHY, Chan ACY, Ma KW, Xia W, Cheung TT. Blocking CDK1/PDK1/_-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma Theranostics. 2018 Jun 13;8(14):3737-3750.

Products Related to Human CDK1/CyclinA1 Active can be found at Proteins